Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that the following documents have today been posted or otherwise made available to shareholders:
In accordance with Listing Rule 9.6.1, a copy of each of these documents has been uploaded to the National Storage Mechanism and will be available for viewing shortly.
The 2012 Annual Report and Accounts and Notice of the 2013 Annual General Meeting are also available on Shire’s website at www.shire.com.
Disclosure & Transparency Rule (“DTR”) 6.3.5 requires the Company to disclose to the media certain information from its Annual Report, if that information is of a type that would be required to be disseminated in a half-yearly report. Accordingly, the Appendix to this announcement contains a management report and the directors’ responsibility statement. It should be read in conjunction with the Company’s unaudited full year results for the year ended December 31, 2012, issued on February 14, 2013 which comprises the Company’s consolidated financial statements prepared under U.S. GAAP. The Appendix together with the unaudited full year results constitute the material required by DTR 6.3.5 to be communicated to the media in unedited full text through a Regulated Information Service. This material is not a substitute for reading the full 2012 Annual Report.
The information included in the Appendix is extracted from the 2012 Annual Report which was approved by the Directors on February 25, 2013.
Deputy Company Secretary
For further information please contact:
Eric Rojas ([email protected])
+1 781 482 0999
Sarah Elton-Farr ([email protected])
+44 1256 894 157
Notes to editors
Shire plc (the “Company”) and its subsidiaries (collectively “Shire” or the “Group”) develop and provide healthcare in the areas of:
as well as other symptomatic conditions treated by specialist physicians. To serve different patient groups, Shire operates in three distinct business units: Specialty Pharmaceuticals (“SP”), Human Genetic Therapies (“HGT”) and Regenerative Medicine (“RM”).
For further information about Shire, please visit our website: www.shire.com.
The “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:
and other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange Commission, including those risks outlined on pages 26 to 32 of the full release.
Click here for the PDF version of this press release.